207 related articles for article (PubMed ID: 22432742)
1. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients.
Sun HY; Wagener M; Cacciarelli TV; Singh N
Clin Transplant; 2012; 26(6):849-52. PubMed ID: 22432742
[TBL] [Abstract][Full Text] [Related]
2. Impact of pretransplant rifaximin therapy on early post-liver transplant infections.
Esfeh JM; Hanouneh IA; Koval CE; Kovacs C; Dalal DS; Ansari-Gilani K; Confer BD; Eghtesad B; Zein NN; Menon KV
Liver Transpl; 2014 May; 20(5):544-51. PubMed ID: 24493238
[TBL] [Abstract][Full Text] [Related]
3. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
4. Identifying a targeted population at high risk for infections after liver transplantation in the MELD era.
Sun HY; Cacciarelli TV; Singh N
Clin Transplant; 2011; 25(3):420-5. PubMed ID: 20482564
[TBL] [Abstract][Full Text] [Related]
5. Rifaximin for the treatment of hepatic encephalopathy.
Mantry PS; Munsaf S
Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
[TBL] [Abstract][Full Text] [Related]
6. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy.
Neff GW; Kemmer N; Zacharias VC; Kaiser T; Duncan C; McHenry R; Jonas M; Novick D; Williamson C; Hess K; Thomas M; Buell J
Transplant Proc; 2006 Dec; 38(10):3552-5. PubMed ID: 17175328
[TBL] [Abstract][Full Text] [Related]
7. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
8. Transjugular intrahepatic portosystemic shunts in liver transplant recipients for management of refractory ascites: clinical outcome.
Saad WE; Darwish WM; Davies MG; Waldman DL
J Vasc Interv Radiol; 2010 Feb; 21(2):218-23. PubMed ID: 20123207
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
[TBL] [Abstract][Full Text] [Related]
11. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
Williams R; Bass N
Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin: new therapeutic indication and future directions.
Rivkin A; Gim S
Clin Ther; 2011 Jul; 33(7):812-27. PubMed ID: 21741091
[TBL] [Abstract][Full Text] [Related]
13. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center.
Agopian VG; Petrowsky H; Kaldas FM; Zarrinpar A; Farmer DG; Yersiz H; Holt C; Harlander-Locke M; Hong JC; Rana AR; Venick R; McDiarmid SV; Goldstein LI; Durazo F; Saab S; Han S; Xia V; Hiatt JR; Busuttil RW
Ann Surg; 2013 Sep; 258(3):409-21. PubMed ID: 24022434
[TBL] [Abstract][Full Text] [Related]
14. Impact of Rifaximin Therapy on Ischemia/Reperfusion Injury in Liver Transplantation: A Propensity Score-Matched Analysis.
Ito T; Nakamura K; Kageyama S; Korayem IM; Hirao H; Kadono K; Aziz J; Younan S; DiNorcia J; Agopian VG; Yersiz H; Farmer DG; Busuttil RW; Kupiec-Weglinski JW; Kaldas FM
Liver Transpl; 2019 Dec; 25(12):1778-1789. PubMed ID: 31509643
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.
Mantry PS; Mehta A; Graydon R
Transplant Proc; 2014 Dec; 46(10):3481-6. PubMed ID: 25498076
[TBL] [Abstract][Full Text] [Related]
16. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
17. Impact of preoperative serum sodium concentration in living donor liver transplantation.
Fukuhara T; Ikegami T; Morita K; Umeda K; Ueda S; Nagata S; Sugimachi K; Gion T; Yoshizumi T; Soejima Y; Taketomi A; Maehara Y
J Gastroenterol Hepatol; 2010 May; 25(5):978-84. PubMed ID: 20546453
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin for the treatment of hepatic encephalopathy.
Lawrence KR; Klee JA
Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
[TBL] [Abstract][Full Text] [Related]
20. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
